Insider Selling: Beigene, Ltd. (NASDAQ:ONC) Insider Sells 41,760 Shares of Stock

Beigene, Ltd. (NASDAQ:ONC - Get Free Report) insider Xiaodong Wang sold 41,760 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $262.82, for a total value of $10,975,363.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, May 13th, Xiaodong Wang sold 41,760 shares of Beigene stock. The shares were sold at an average price of $223.50, for a total value of $9,333,360.00.
• On Monday, April 14th, Xiaodong Wang sold 41,760 shares of Beigene stock. The shares were sold at an average price of $242.66, for a total value of $10,133,481.60.
• On Tuesday, March 18th, Xiaodong Wang sold 41,760 shares of Beigene stock. The stock was sold at an average price of $261.28, for a total value of $10,911,052.80.

Beigene Price Performance

Beigene stock traded down $6.90 during mid-day trading on Friday, reaching $269.63. 391,727 shares of the company were exchanged, compared to its average volume of 451,056. The firm's fifty day simple moving average is $241.38. Beigene, Ltd. has a 12 month low of $141.31 and a 12 month high of $287.88. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05. The company has a market cap of $29.52 billion, a price-to-earnings ratio of -32.72, a PEG ratio of 7.73 and a beta of 0.30.

Beigene (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. Sell-side analysts anticipate that Beigene, Ltd. will post -5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ONC. Sanford C. Bernstein set a $259.00 price target on Beigene in a report on Thursday, March 13th. Royal Bank of Canada dropped their price target on Beigene from $312.00 to $311.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Macquarie lifted their price target on Beigene from $259.00 to $313.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Bank of America raised Beigene from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $207.00 to $320.00 in a report on Monday, March 3rd. Finally, TD Securities reissued a "buy" rating and set a $334.00 price target on shares of Beigene in a report on Thursday, April 24th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Beigene presently has a consensus rating of "Buy" and a consensus target price of $319.00.

About Beigene

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.